Navigation Links
Review of probiotic research finds only Bifantis can claim efficacy vs. placebo for IBS symptoms
Date:10/15/2007

PHILADELPHIA October 15, 2007 A new analysis of randomized controlled trials evaluating probiotics in the treatment of irritable bowel syndrome (IBS) has found that Bifantis, Bifidobacterium infantis 35624, the sole ingredient in Align (manufactured by Procter & Gamble), is the only probiotic currently able to demonstrate significant improvement in IBS symptoms based upon a properly designed research study. Researchers at the University of Michigan conducted the review to evaluate the safety, efficacy and tolerability of probiotics for IBS in randomized controlled trials and found that, with the exception of the Bifidobacterium infantis 35624 studies, most were not designed in a way that made the data possible to validate. The review data were presented this week at the annual American College of Gastroenterology (ACG) conference taking place in Philadelphia, PA.

There is growing interest in medical and patient communities about the use of probiotics in IBS and lots of data has been published about this topic, but its helpful to know the quality of that data before making a treatment decision, said Darren Brenner, MD, lead investigator on this project. Our analysis showed that only this particular strain of probiotic, Bifidobacterium infantis 35624, has valid data for successfully treating IBS symptoms. At this point, we just dont have enough valid data to determine if other probiotics are effective for IBS.

The Study

The goal of this systematic review of randomized controlled trials was to evaluate the efficacy, safety and tolerability of probiotics in the treatment of IBS. Criteria for the study included randomized controlled trials testing adults with IBS symptoms using single or combination probiotics versus placebo for IBS symptoms and frequency of adverse events.

Of the 13 trials that met selection criteria, 11 demonstrated sub-optimal study design with inadequate blinding, inadequate trial length, inadequate sample size and lack of proper analysis. Only three studies provided quantifiable data about tolerability and adverse events, and the only probiotic to demonstrate significant improvement in IBS symptoms in appropriately designed studies was Bifidobacterium infantis 35624.

Bifidobacterium infantis 35624 showed significant improvement in the composite score of abdominal pain/discomfort, bloating/distention and bowel movement difficulty compared with placebo. A subsequent study showed that Bifidobacterium infantis 35624 demonstrated superior efficacy to the placebo for the primary outcome measure of abdominal pain/discomfort as well as for secondary measures including bloating/distention, incomplete evacuation, straining and passage of gas.

From our discovery of the bacterium to the description of its genome and biological properties and, finally, to the clinical studies that have made this available to consumers in Align, our primary goal has been to provide accurate information on the benefits of Bifantis, said Eamonn Quigley, MD FACG and professor of Medicine and Human Physiology and Head of the Medical School, National University of Ireland (NUI).


'/>"/>

Contact: Shirley Johnson
Shirley.Johnson@mslpr.com
Manning Selvage & Lee
Source:Eurekalert

Related medicine news :

1. FDA may speed review of new drugs
2. Scientists review SARS
3. US Reviews Risks Of Tamiflu After 12 Children Die
4. Breast Cancer Examinations To Be Reviewed In Irish Hospitals
5. BioCryst’s Bird Flu Drug Enjoys Fast-Track Review By FD
6. A Sneak Preview of Human’s Susceptibility to Auto Immune Disease, Allergy, Asthm
7. Thumbs up in weight loss for vegetarian diets: scientific review
8. FDA Accords Priority Review For Pediatric Crohns Disease Drug
9. The Lancet Calls For Review Of Regulatory Process Of Drug Trials
10. Review of Pramod Mahajans Injuries
11. Vaticans Council Reviews Condom Usage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... ... 2016 , ... EB Medicine presented its first-ever “Issue of ... in Ponte Vedra Beach, FL. The awards honor the outstanding work of leading ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the efforts ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 Research and ... "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" report ... In-Mold Electronics, Smart Skin, Structural Health Monitoring, ... Structural electronics involves electronic and/or electrical components ... replacing dumb structures such as vehicle bodies or ...
(Date:6/24/2016)... 2016 Research and Markets has announced ... Diagnostic Tests" report to their offering. ... The World Market for Companion Diagnostics covers ... Market analysis in the report includes the following: ... Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology: